Gantacurium chloride

Drug Profile

Gantacurium chloride

Alternative Names: AV 430A; Gantacurium; GW-280430

Latest Information Update: 02 Feb 2011

Price : $50

At a glance

  • Originator Avera Pharmaceuticals
  • Class Anaesthetics; Isoquinolines
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anaesthesia

Most Recent Events

  • 02 Feb 2011 No development reported - Phase-II for Anaesthesia in USA (IV-injection)
  • 29 Jun 2006 Avera Pharmaceuticals has completed a phase II trial with gantacurium as an adjunct to general anaesthesia in the US
  • 30 Nov 2005 Phase-II clinical trials in Anaesthesia in USA (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top